Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives

Japanese Journal of Clinical Oncology
Koji MatsumotoNobuo Yaegashi

Abstract

Several 'lines of therapy' that utilize cytotoxic agents and are driven by platinum-free intervals are the current standard of care for patients with recurrent ovarian cancer. For patients with platinum-resistant disease, single agent chemotherapy (pegylated liposomal doxorubicin, topotecan, gemcitabine or weekly paclitaxel) is the standard of care. For patients with platinum-sensitive disease, combination chemotherapy (carboplatin plus paclitaxel, pegylated liposomal doxorubicin or gemcitabine) is the standard of care. In addition, antiangiogenic therapy using bevacizumab is an established option. Future directions could include 'lines of therapy' with biologic agents driven by specific biologic targets. Data from antiangiogenic agents (trebananib, pazopanib and cediranib), antifolate drugs (farletuzumab and vintafolide), poly(ADP-ribose) polymerase inhibitors (olaparib and veliparib), mTOR inhibitors (everolimus and temsirolimus) and immune editing agents (nivolumab) have been summarized in this review.

References

Mar 11, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MarkmanJ L Lewis
Sep 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jacobus PfistererUNKNOWN EORTC GCG
Jul 3, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David G MutchAngeles Alvarez Secord
Mar 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gunter von MinckwitzSibylle Loibl
Jun 12, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·I VergoteUNKNOWN ASSIST-1 Study Group
May 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Pujade-LauraineAndreas du Bois
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bradley J MonkAndrés M Poveda
Feb 3, 2011·JAMA : the Journal of the American Medical Association·Vishal RanpuraShenhong Wu
Dec 30, 2011·The New England Journal of Medicine·Robert A BurgerUNKNOWN Gynecologic Oncology Group
Dec 30, 2011·The New England Journal of Medicine·Timothy J PerrenUNKNOWN ICON7 Investigators
Mar 29, 2012·The New England Journal of Medicine·Jonathan LedermannUrsula Matulonis
Aug 23, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L C HankerUNKNOWN AGO and GINECO study group
Nov 22, 2012·The Lancet Oncology·Jaafar BennounaUNKNOWN ML18147 Study Investigators
Oct 16, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R Wendel NaumannRichard A Messmann
Mar 19, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Pujade-LauraineIsabelle Ray-Coquard

❮ Previous
Next ❯

Citations

Apr 20, 2017·The Journal of Obstetrics and Gynaecology Research·Tatsuya IshiguroTakayuki Enomoto
Jul 28, 2019·Cancers·Laurie G HudsonAngela Wandinger-Ness
Aug 14, 2018·Pharmacological Reports : PR·Daohua ShiJintuo Zhou
Nov 17, 2020·International Journal of Cancer. Journal International Du Cancer·Roy KessousWalter H Gotlieb
Sep 1, 2018·Pharmacological Reports : PR·Daohua ShiJintuo Zhou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.